These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 24395569)

  • 1. Systemic administration of a cyclic signal transducer and activator of transcription 3 (STAT3) decoy oligonucleotide inhibits tumor growth without inducing toxicological effects.
    Sen M; Paul K; Freilino ML; Li H; Li C; Johnson DE; Wang L; Eiseman J; Grandis JR
    Mol Med; 2014 Mar; 20(1):46-56. PubMed ID: 24395569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of toxicity of a STAT3 decoy oligonucleotide.
    Sen M; Tosca PJ; Zwayer C; Ryan MJ; Johnson JD; Knostman KA; Giclas PC; Peggins JO; Tomaszewski JE; McMurray TP; Li C; Leibowitz MS; Ferris RL; Gooding WE; Thomas SM; Johnson DE; Grandis JR
    Cancer Chemother Pharmacol; 2009 May; 63(6):983-95. PubMed ID: 18766340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-X(L) enhances antitumor effects in squamous cell carcinoma of the head and neck.
    Boehm AL; Sen M; Seethala R; Gooding WE; Freilino M; Wong SM; Wang S; Johnson DE; Grandis JR
    Mol Pharmacol; 2008 Jun; 73(6):1632-42. PubMed ID: 18326051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. STAT3 oligonucleotide inhibits tumor angiogenesis in preclinical models of squamous cell carcinoma.
    Klein JD; Sano D; Sen M; Myers JN; Grandis JR; Kim S
    PLoS One; 2014; 9(1):e81819. PubMed ID: 24404126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STAT3 decoy oligonucleotide-carrying microbubbles with pulsed ultrasound for enhanced therapeutic effect in head and neck tumors.
    Ramasamy T; Chen X; Qin B; Johnson DE; Grandis JR; Villanueva FS
    PLoS One; 2020; 15(11):e0242264. PubMed ID: 33206698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ultrasound Targeted Microbubble Destruction-Mediated Delivery of a Transcription Factor Decoy Inhibits STAT3 Signaling and Tumor Growth.
    Kopechek JA; Carson AR; McTiernan CF; Chen X; Hasjim B; Lavery L; Sen M; Grandis JR; Villanueva FS
    Theranostics; 2015; 5(12):1378-87. PubMed ID: 26681983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiproliferative mechanisms of a transcription factor decoy targeting signal transducer and activator of transcription (STAT) 3: the role of STAT1.
    Lui VW; Boehm AL; Koppikar P; Leeman RJ; Johnson D; Ogagan M; Childs E; Freilino M; Grandis JR
    Mol Pharmacol; 2007 May; 71(5):1435-43. PubMed ID: 17325127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy.
    Sen M; Thomas SM; Kim S; Yeh JI; Ferris RL; Johnson JT; Duvvuri U; Lee J; Sahu N; Joyce S; Freilino ML; Shi H; Li C; Ly D; Rapireddy S; Etter JP; Li PK; Wang L; Chiosea S; Seethala RR; Gooding WE; Chen X; Kaminski N; Pandit K; Johnson DE; Grandis JR
    Cancer Discov; 2012 Aug; 2(8):694-705. PubMed ID: 22719020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockage of the STAT3 signaling pathway with a decoy oligonucleotide suppresses growth of human malignant glioma cells.
    Gu J; Li G; Sun T; Su Y; Zhang X; Shen J; Tian Z; Zhang J
    J Neurooncol; 2008 Aug; 89(1):9-17. PubMed ID: 18415045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inorganic kernel - Supported asymmetric hybrid vesicles for targeting delivery of STAT3-decoy oligonucleotides to overcome anti-HER2 therapeutic resistance of BT474R.
    Shi K; Fang Y; Gao S; Yang D; Bi H; Xue J; Lu A; Li Y; Ke L; Lin X; Jin X; Li M
    J Control Release; 2018 Jun; 279():53-68. PubMed ID: 29655990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitory effects of STAT3 decoy oligodeoxynucleotides on human epithelial ovarian cancer cell growth in vivo.
    Zhang X; Liu P; Zhang B; Mao H; Shen L; Ma Y
    Int J Mol Med; 2013 Sep; 32(3):623-8. PubMed ID: 23828376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy.
    Xi S; Gooding WE; Grandis JR
    Oncogene; 2005 Feb; 24(6):970-9. PubMed ID: 15592503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic effects of STAT3 decoy oligodeoxynucleotide on human lung cancer in xenograft mice.
    Zhang X; Zhang J; Wang L; Wei H; Tian Z
    BMC Cancer; 2007 Aug; 7():149. PubMed ID: 17683579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inorganic Kernel-Reconstituted Lipoprotein Biomimetic Nanovehicles Enable Efficient Targeting "Trojan Horse" Delivery of STAT3-Decoy Oligonucleotide for Overcoming TRAIL Resistance.
    Shi K; Xue J; Fang Y; Bi H; Gao S; Yang D; Lu A; Li Y; Chen Y; Ke L
    Theranostics; 2017; 7(18):4480-4497. PubMed ID: 29158840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical Properties of a Decoy Oligodeoxynucleotide Inhibitor of STAT3 Transcription Factor.
    Lee DS; O'Keefe RA; Ha PK; Grandis JR; Johnson DE
    Int J Mol Sci; 2018 May; 19(6):. PubMed ID: 29848966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. STAT3-decoy oligodeoxynucleotide inhibits the growth of human lung cancer via down-regulating its target genes.
    Zhang X; Zhang J; Wei H; Tian Z
    Oncol Rep; 2007 Jun; 17(6):1377-82. PubMed ID: 17487394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death.
    Li C; Zang Y; Sen M; Leeman-Neill RJ; Man DS; Grandis JR; Johnson DE
    Mol Cancer Ther; 2009 Aug; 8(8):2211-20. PubMed ID: 19638453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A STAT3-decoy oligonucleotide induces cell death in a human colorectal carcinoma cell line by blocking nuclear transfer of STAT3 and STAT3-bound NF-κB.
    Souissi I; Najjar I; Ah-Koon L; Schischmanoff PO; Lesage D; Le Coquil S; Roger C; Dusanter-Fourt I; Varin-Blank N; Cao A; Metelev V; Baran-Marszak F; Fagard R
    BMC Cell Biol; 2011 Apr; 12():14. PubMed ID: 21486470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth.
    Leong PL; Andrews GA; Johnson DE; Dyer KF; Xi S; Mai JC; Robbins PD; Gadiparthi S; Burke NA; Watkins SF; Grandis JR
    Proc Natl Acad Sci U S A; 2003 Apr; 100(7):4138-43. PubMed ID: 12640143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Stat3 abrogates EGFR inhibitor resistance in cancer.
    Sen M; Joyce S; Panahandeh M; Li C; Thomas SM; Maxwell J; Wang L; Gooding WE; Johnson DE; Grandis JR
    Clin Cancer Res; 2012 Sep; 18(18):4986-96. PubMed ID: 22825581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.